Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (3): 248-254.doi: 10.3969/j.issn.1000-6621.2021.03.010
• Original Articles • Previous Articles Next Articles
WANG Xi-jiang*, TAN Yun-hong, HE Wen-cong, OU Xi-chao, LIU Dong-xin, ZHAO Yan-lin()
Received:
2020-10-29
Online:
2021-03-10
Published:
2021-03-03
Contact:
ZHAO Yan-lin
E-mail:zhaoyl@chinacdc.cn
WANG Xi-jiang, TAN Yun-hong, HE Wen-cong, OU Xi-chao, LIU Dong-xin, ZHAO Yan-lin. The correlation between rifampicin and isoniazid resistance-related gene mutations and resistance level in Mycobacterium tuberculosis[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 248-254. doi: 10.3969/j.issn.1000-6621.2021.03.010
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.03.010
名称 | 耐药基因 | 表型耐药菌株数 | |
---|---|---|---|
突变位点 | 菌株数(构成比,%) | ||
rpoB | Asp435Tyr | 1(1.41) | 1 |
Asp435Val | 2(2.82) | 2 | |
Asp435Gly+Leu430Arg | 1(1.41) | 1 | |
His445Asp | 4(5.63) | 4 | |
His445Leu | 5(7.04) | 5 | |
His445Tyr | 4(5.63) | 4 | |
His445Gln+Leu430Pro | 1(1.41) | 1 | |
His445Arg+Gln429His | 1(1.41) | 1 | |
His445Tyr+Asp435Phe | 5(7.04) | 5 | |
Ile491Phe | 1(1.41) | 1 | |
Leu430Pro | 1(1.41) | 0 | |
Leu430Pro+Ser431Gly | 3(4.22) | 3 | |
Leu443Trp+Thr444Pro | 2(2.82) | 2 | |
Leu452Pro | 3(4.22) | 3 | |
Ser441Leu | 2(2.82) | 2 | |
Ser450Leu | 31(43.66) | 31 | |
Ser450Phe | 1(1.41) | 1 | |
Ser450Trp | 1(1.41) | 1 | |
rpoB+rpoC | Leu452Pro+Ile885Val | 1(1.41) | 1 |
Ser450Leu+Gly332Arg | 1(1.41) | 1 | |
合计 | 71(100.00) | 70 |
名称 | 耐药基因 | 表型耐药菌株数 | |
---|---|---|---|
突变位点 | 表型耐药菌株数(构成比,%) | ||
ahpC | G-48A promoter | 3(2.94) | 3 |
C-52T promoter | 1(0.98) | 1 | |
C-54T promoter | 1(0.98) | 1 | |
C-81T promoter | 2(1.96) | 2 | |
C-81T+G-74A promoter | 1(0.98) | 1 | |
katG | Ala109Val | 1(0.98) | 1 |
Ser315Asn | 13(12.75) | 13 | |
Ser315Thr | 57(55.88) | 57 | |
Val1Ala | 1(0.98) | 1 | |
146_147insTGCA | 1(0.98) | 1 | |
fabG1 | C-15T promoter | 9(8.83) | 9 |
fabG1+ahpC | C-15T promoter+G-48A promoter | 1(0.98) | 1 |
fabG1+inhA | C-15T promoter+Ile21Val | 1(0.98) | 1 |
fabG1+katG | C-15T promoter+Tyr155Cys | 1(0.98) | 1 |
C-15T+Tyr155Cys+Ser315Thr | 1(0.98) | 1 | |
C-15T promoter+Ser315Thr | 1(0.98) | 1 | |
C-15T promoter+Tyr155Cys | 2(1.96) | 2 | |
C-15T promoter+Ala106Val | 1(0.98) | 1 | |
katG+ahpC | 1472_1473insG+C-54T promoter | 1(0.98) | 1 |
1856_1857insT+C-81T promoter | 1(0.98) | 1 | |
Thr380Ile+C-52T promoter | 1(0.98) | 1 | |
Tyr413His+G-48A promoter | 1(0.98) | 1 | |
合计 | 102(100.00) | 102 |
[1] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[2] |
Rosales-Klintz S, Jureen P, Zalutskayae A, et al. Drug resis-tance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions. Int J Mycobacteriol, 2012,1(3):124-130. doi: 10.1016/j.ijmyco.2012.08.001.
doi: 10.1016/j.ijmyco.2012.08.001 URL pmid: 26787207 |
[3] |
Seifert M, Catanzaro D, Catanzaro A, et al. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One, 2015,10(3):e0119628. doi: 10.1371/journal.pone.0119628.
doi: 10.1371/journal.pone.0119628 URL pmid: 25799046 |
[4] | 赵雁林, 逄宇. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015: 32. |
[5] |
Abuali MM, Katariwala R, LaBombardi VJ. A comparison of the Sensititre(R) MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol, 2012,31(5):835-839. doi: 10.1007/s10096-011-1382-z.
doi: 10.1007/s10096-011-1382-z URL |
[6] |
Hall L, Jude KP, Clark SL, et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J Clin Microbiol, 2012,50(11):3732-3734. doi: 10.1128/JCM.02048-12.
doi: 10.1128/JCM.02048-12 URL pmid: 22895034 |
[7] | 郑扬, 夏辉, 赵雁林. TREK Sensititre® MYCOTB 检测结核分枝杆菌对一、二线抗结核药物的敏感性研究 . 中国防痨杂志, 2015,37(6):597-602. doi: 10.3969/j.issn.1000-6621.2015.06.005. |
[8] |
Coll F, McNerney R, Preston M, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med, 2015,7(1):51. doi: 10.1186/s13073-015-0164-0.
doi: 10.1186/s13073-015-0164-0 URL pmid: 26019726 |
[9] |
Miotto P, Zhang Y, Cirillo DM, et al. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 2018,23(12):1098-1113. doi: 10.1111/resp.13393.
doi: 10.1111/resp.13393 URL pmid: 30189463 |
[10] |
Madrazo-Moya CF, Cancino-Munoz I, Cuevas-Cordoba B, et al. Whole genomic sequencing as a tool for diagnosis of drug and multidrug-resistance tuberculosis in an endemic region in Mexico. PLoS One, 2019,14(6):e0213046. doi: 10.1371/journal.pone.0213046.
doi: 10.1371/journal.pone.0213046 URL pmid: 31166945 |
[11] | Kardan-Yamchi J, Kazemian H, Battaglia S, et al. Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran. J Clin Med, 2020,9(2):465. doi: 10.3390/jcm9020465. |
[12] | Tang K, Sun H, Zhao Y, et al. Characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Sichuan in China. Tuberculosis (Edinb), 2013,93(1):89-95. doi: 10.1016/j.tube.2012.10.009. |
[13] |
Tavanaee Sani A, Ashna H, Kaffash A, et al. Mutations of rpob Gene Associated with Rifampin Resistance among Mycobacterium Tuberculosis Isolated in Tuberculosis Regional Reference Laboratory in Northeast of Iran during 2015-2016. Ethiop J Health Sci, 2018,28(3):299-304. doi: 10.4314/ejhs.v28i3.7.
doi: 10.4314/ejhs.v28i3.7 URL pmid: 29983529 |
[14] | Andre E, Goeminne L, Colmant A, et al. Novel rapid PCR for the detection of Ile491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect, 2017,23(4):267.e5-267.e7. doi: 10.1016/j.cmi.2016.12.009. |
[15] | Chen L, Gan X, Li N, et al. rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China. J Antimicrob Chemoth, 2010,65(6):1299-1301. doi: 10.1093/jac/dkq102. |
[16] |
Jamieson FB, Guthrie JL, Neemuchwala A, et al. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol, 2014,52(6):2157-2162. doi: 10.1128/JCM.00691-14.
doi: 10.1128/JCM.00691-14 URL pmid: 24740074 |
[17] |
Van Deun A, Aung KJ, Bola V, et al. Rifampin drug resis-tance tests for tuberculosis: challenging the gold standard. J Clin Microbiol, 2013,51(8):2633-2640. doi: 10.1128/JCM.00553-13.
doi: 10.1128/JCM.00553-13 URL pmid: 23761144 |
[18] |
Torrea G, Ng K, Van Deun A, et al. Variable ability of rapid tests to detect mycobacterium tuberculosis rpob mutations conferring phenotypically occult rifampicin resistance. Scientific reports, 2019,9:11826. doi: 10.1038/s41598-019-48401-z.
doi: 10.1038/s41598-019-48401-z URL pmid: 31413308 |
[19] | Liu L, Jiang F, Chen L, et al. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerg Microbes Infec, 2018,7(1):183. doi: 10.1038/s41426-018-0184-0. |
[20] | Dookie N, Rambaran S, Padayatchi N, et al. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemoth, 2018,73(5):1138-1151. doi: 10.1093/jac/dkx506. |
[21] | Jagielski T, Bakula Z, Roeske K, et al. Mutation profiling for detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemoth, 2015,70(12):3214-3221. doi: 10.1093/jac/dkv253. |
[22] |
Zhang M, Yue J, Yang YP, et al. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol, 2005,43(11):5477-5482. doi: 10.1128/JCM.43.11.5477-5482.2005.
doi: 10.1128/JCM.43.11.5477-5482.2005 URL pmid: 16272473 |
[23] |
Kigozi E, Kasule GW, Musisi K, et al. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One, 2018,13(5):e0198091. doi: 10.1371/journal.pone.0198091.
doi: 10.1371/journal.pone.0198091 URL pmid: 29847567 |
[24] |
Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2008,12(2):139-145.
URL pmid: 18230245 |
[25] |
Walsh KF, Vilbrun SC, Souroutzidis A, et al. Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti. Clin Infect Dis, 2019,69(4):717-719. doi: 10.1093/cid/ciz039.
doi: 10.1093/cid/ciz039 URL pmid: 30698688 |
[26] |
Colangeli R, Jedrey H, Kim S, et al. Bacterial Factors That Predict Relapse after Tuberculosis Therapy. New Engl J Med, 2018,379(9):823-833. doi: 10.1056/NEJMoa1715849.
doi: 10.1056/NEJMoa1715849 URL pmid: 30157391 |
[1] | SHU Wei, GE Qi-ping, HUANG Xue-rui, MA Li-ping, JI Bin-ying, CHEN Yu-hui, CHEN Xiao-you, JIANG Guang-lu, XIE Li, LI Bo, CHEN Sheng-yu, CHEN Sen-lin, YAN Jun-ping, SHI Lian, CHEN Ling, LI You-lun, XI Xiu-e, LIU Qian-ying, YAN Xing-lu, WANG Fei, WANG Fu-rong, WU Xiang, ZHANG Peng, LENG Xue-yan, CAO Wen-li, ZHANG Hai-qing, CUI Hong-zhe, YANG Cheng-qing, WU Chao, LI Juan, LI Hua, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, NING Yu-jia, TIAN Xi-zhong, DU Jian, LI Liang, GAO Wei-wei. Analysis of treatment outcomes of retreated pulmonary tuberculosis patients with isoniazid-resistance and rifampin-resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 322-327. |
[2] | YANG Qing-luan, LIU Qi-hui, LIN Miao-yao, XU Yu-zhen, LIU Xue-feng, HE Zhang-yu-fan, HUANG Xi-tian, HAO Bin, SHAO Ling-yun, ZHANG Wen-hong, RUAN Qiao-ling. A study of pharmacokinetic of rifapentine combined with isoniazid in the preventive treatment of tuberculosis in silicotic patients [J]. Chinese Journal of Antituberculosis, 2021, 43(3): 228-232. |
[3] | CUI Xiao-jing, WEI Dong, WANG Chun-lei, CAO Bin. Value of molecular diagnosis and liquid culture methods in improving the pathogenic diagnosis of pulmonary tuberculosis in general hospitals [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 143-146. |
[4] | LI Yuan-chun, ZHANG Yue, ZENG Xiang-jie, HE Wen-cong, QIU Qian, ZHAO Yan-lin, LI Yan-ming. Subspecies and in vitro drug sensitivity analysis of Mycobacterium intracellular clinical isolates [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 147-152. |
[5] | CAO Xin-yu, XUE Miao, WEN Yan, LIU Li. Research progress on susceptibility genes of anti-tuberculous drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 190-193. |
[6] | LIU Zhi-bin, WU Min, WU Xiao-cui, HAN Min, XIAO He-ping, ZHANG Qing. The value of PCR-reverse dot blot hybridization in detecting the drug resistance of Mycobacterium tuberculosis in sputum specimens of retreatment smear-positive pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 47-51. |
[7] | LI Qian, WANG Lin-bao, LUO Pei-jia, WEI Lin, LIU Yu-gang, REN Lei-peng, DING Chao. Analysis of the results of etiology and drug resistance in different surgical specimens of tuberculous empyema by two techniques [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 52-57. |
[8] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[9] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[10] | BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724. |
[11] | LIANG Xiao-yan, LIN Mei, LIANG Da-bin, LAN Ru-shu, QIN Hui-fang, YE Jing, HUANG Li-wen. Drug resistance and genotypic characteristics of multidrug-resistant Mycobacterium tuberculosis in Guangxi Zhuang Autonomous Region [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 578-582. |
[12] | MA Jin-bao, REN Fei, ZENG Ling-cheng, CHEN Ming-wei. Analysis of drug susceptibility of 680 patients with multidrug-resistant tuberculosis in Xi’an City from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 609-613. |
[13] | QIN Zhong-hua, JING Ye, DU Yan-qing, SONG Xiao-mei, ZHANG Li-xia. Spectrum and drug resistance analysis of 339 strains of nontuberculous mycobacterium isolated from clinical practice [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 630-633. |
[14] | ZHANG Jing, CHEN Xi, WANG Bin, FU Lei, LU Yu, CHEN Xiao-you. Establishment of modified propidium monoazide (PMAxx)-quantitative PCR assay and its application for identification of antituberculosis drug activity [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 472-480. |
[15] | LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||